Aptamers and cancer

Nasrin Yazdanpanahi, Mehrdad Hashemi, Abolfazl Movafagh



Oligonucleotides Aptamers are single strands of DNA and RNA with the length of 20-100 nucleotides or peptides and unique three dimensional structure that is affected by nucleotide sequence. The structure exclusively influences aptamers’ bindings with its target molecule. It reduces performance or inactivate protein and this feature is used for therapeutic purposes. In addition and through connecting to signature molecule, aptamers are used to detect specific proteins. High efficiency of aptamer technology makes them a valuable tool for diagnosing and treating different diseases including cancer. The present study is an attempt to review recent studies in this field.


Keywords: aptamer, canter, SELEX technique

Full Text:




Strehlitz B, Nikolaus N, Stoltenburg R. Protein detection

with aptamer biosensors. sensors 2008; 8: 4296-4307.

Javaherian S, Musheev MU, Kanoatov M, Berezovski M

V, Krylov SN. Selection of aptamers for a protein target

in cell lysate and their application to protein purification.

Nucleic Acid research 2009; 37(8): e62.

Barbas SA, White RR. The development and testing of

aptamers for cancer. Current Opinion in Investigational

Drugs 2009; 10(6): 572-578.

Pieve C Da, Iley JN, Parkins A, Missailidis S.

Development of anti-Muc1 DNA aptamers for the

imaging and radiotherapy of breast cancer. Breast

Cancer Research 2006; 8(suppl 2).

Collett JR, Cho EJ, Ellington DA. Production and

processing of aptamer microarrays methods 2005; 37:


Yilin L, Lei G, Zhao Yang Z, Jijun T, Jianwei X.Recent

advances of aptamer sensors. Science in China Series B;

Chemistry March 2008; 51(3): 193-204.

Hasegawa H, Ken-ichi T, Sode K, Ikebukuro K.

Improvement of aptamer affinity by dimerization.

Sensors 2008; 8: 1090-1098.

Wu ZS, Zheng F, Shen GL, Yu RQ. A hairpin aptamerbased

electrochemical biosencing platform for the

sensitive detection of proteins. Biomaterials 2009; 30:


HER2 and HER3 Aptamers [database on the intrnet].

The Regents of the University of California (UCLA):

[cited 2009 May 4]. Available from: http:// www.


Pestourie C, Tavitian B, Duconge F. Aptamer agains

extracellular targets for in vivo applications. Biochimie

Sep-Oct 2005; 87(9-10):921-930.

Lee JO, SO HM, Jeon KE, Chang H,Won K, Kim

YH. Aptamers as molecular recognation elements for

electrical nanobiosensors. Anal Bioanal Chem 2008;

: 1023-1032.

Tombelli S, Minunni M, Mascini M. Analytical

applications of aptamers. Biosens Bioelectron Jun

; 20(12): 2424-2434.

Nitsche A, Kurth A, Dunkhorst A, Panke O, Sielaff H,

Junge W, et al. One step selection of vaccina virus-binding

DNA aptamers by monolex. BMC Biotechnology 2007;

: 48.

Balamurugan S, Obubuafo A, Soper AS, Spivak AD.

Surface immobilization methods for aptamer diagnostic

applications. Anal Bioanal Chem 2008; 390: 1009-1021.

Ferreira CSM, Papamichael K, Guilbault G,

Schwarzacher T, Gariepy J, Missailidis S. Dna aptamers

againt the Muc1 tumour marker: design of aptamerantibody

sandwich ELIZA for the early diagnosis of

epithelial tumours. Anal Bioanal Chem 2008; 390:


Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW,

Mallikaratchy P, et al. Aptamers evolved from live cells

as effective molecular probs for cancer study. Proc Natl

Acad Sci USA Aug 2006; 103(32):11838-11843.

Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z,

Meng L, et al. Molecular recognation of small-cell lung

cancer cells using aptamers. ChemMedChem 2008; 3:


Srivastava M, Pollard HB. Molecular dissection of

nucleolins role in growth and cell proliferation: new

insights. FASEB J 1999; 13(14): 1911-1922.

Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab

J, Perret E, Deng JS, et al. The cell-surface expressed

nucleolin is associated with the actin cytoskeleton. Exp

Cell Res 2000; 261(2):312-328.

Ireson CR, Kelland LR. Discovery and development

of anticancer aptamers. Mol Cancer Ther 2006; 5(12):


Sennino B, Falcon BL, Mc Cauley D, Le T, Mc Cauley T,

Kurz JC et al. Sequential loss of tumour vessel pericytes

and endothelial cells after inhibition of platelet-derived

growth factor B by selective aptamer AX102. Cancer

Res 2007; 67(15): 7358-7367.

Nakanishi C, Toi M. Nuclear factor-kB inhibitors as

sensitizers to anticancer drug. Nat Rev Cancer 2005;

(4): 297-309.

Karin M, Lin A. NFkB at the crossroads of life and

death. Nat Immunol 2002; 3(3): 221-227.

Mi J, Zhang X, Liu Y, Reddy SK, Sabbani ZN, Sullenger

BA, et al. NF-kB inhibition by an adenovirus expressed

aptamer sensitizes TNFα-induced apoptosis. Biochem

Biophys Res Commun 2007; 359(3): 475-480.

Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, SU Z, et

al. RNA aptamer-targeted inhibition of NF-kB supresses

non-small cell lung cancer resistance to doxorubicin.

Mol Ther 2008; 16(1): 66-73.

Kim KJ, Li B, Winer J, Armannini M, Gillett N, Phillips

HS, Ferrara N. Inhibition of vascular endothelial growth

factor-induced angiogenesis suppresses tumour growth

in vivo. Nature 1993; 362(6423): 841-844.

Ng EW, Shima DT, Calias P, Cunningham ET, Guyer

DR, Adamis AP. Pegaptanib, a targeted anti-VEGF

aptamer for ocular vascular disease. Nat Rev Drug

Disease 2006; 5(2):123-132.

Weber GF, Ashkar S, Contor H. Interaction between

CD44 and osteopontin as a potential basis for metastasis

formation. Proc Assoc Am Physicans 1997; 109(1): 1-9.

Mi Z, Guo H, Russell MB, Liu y, Sullenger BA, Kuo PC.

RNA aptamer blockade of osteopontin inhibits growth

and metastasis of MDA-MB231 breast cancer cells. Mol

Ther 2009; 17(1):153-161.

Tanaka Y, Akagi K, Nakamura Y, Kozu T. RNA aptamers

targeting the carboxy terminus of K RAS oncoprotein

generated by an improved SELEX with isothermal RNA

amplification. Oligonucleotids 2007; 17(1): 12-21.

Tesu O, McCormick F. β catenin regulates expression

of cyclin D1 in colon carcinoma cells. Nature 1999;

(6726): 422-426.

Lee HK, Choi YS, Park YA, Jeong S. Modulation of

oncogenic transcription and altrnative splicing by β

catenin and an RNA aptamer in colon cancer cells.

Cancer Res 2006; 66(21): 10560-10566.

Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni

Y, Gombert K, Tavitian B. Neutralizing aptamers from

whole-cell SELEX inhibit the RET Receptor Tyrosine

Kinase. Plos Biol 2005; 3(4):e123.

Huang YF, Lin YW, Lin ZH, Chang HT. Aptamer

modified gold nanoparticles for targeting breast cancer

cells through light scattering. J Nanopart Res 2009: 775-

Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ.

Targeted delivery of cisplatin to prostate cancer cells

by aptamer functionalized Pt(IV) prodrug-PLGAPEG

nanoparticles. Proc Natl Acad Sci USA 2008;


Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth

S. Cell-specific induction of apoptosis by rationally

designed bivalant aptamer-si RNA transcripts silencing

eukariotic elongation factor 2. Curr Cancer Drug Targets

; 8(7): 554-565

DOI: http://dx.doi.org/10.31557/APJCB.2016.1.1.3


  • There are currently no refbacks.

Copyright (c) 2017 Asian Pacific Journal of Cancer Biology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.





Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention